| ASD | artificial stomach-duodenum model |
| AUC | area under the curve |
| BCS | biopharmaceutics classification system |
| Cmax | maximal concentration |
| CO2 | carbon dioxide |
| CYP | Cytochrome P450 |
| DS | degree of supersaturation |
| EMA | European Medicines Agency |
| FaSSGF | fasted state simulated gastric fluids |
| FaSSIF-v1 | fasted state simulated intestinal fluids version 1 |
| GI | gastrointestinal |
| GIS | gastrointestinal simulator |
| GISDuodenum | duodenal chamber of the GIS |
| GISJejunum | jejunal chamber of the GIS |
| GISStomach | gastric chamber of the GIS |
| HPLC | high-performance liquid chromatography |
| HRM | high-resolution manometry |
| IR | immediate-release |
| ksec_d | secretion rate constant constant occuring in the duodenal chamber of the GIS |
| ksec_s | secretion rate constant constant occuring in the gastric chamber of the GIS |
| M&S | modeling and simulation |
| MTA | mass transport analysis |
| PBBM | physiologically-based biopharmaceutics modeling |
| PBPK | physiologically-based pharmacokinetics modeling |
| PDMA | Pharmaceuticals and Medical Devices Agency |
| PK | pharmacokinetics |
| PPI | proton-pump inhibitor |
| RLD | reference listed drug |
| t1/2,G | gastric half-life of emptying |
| TFA | trifluoroacetic acid |
| U.S. FDA | United States Food and Drug Administration |
| USP | United States Pharmacopoeia |
| Vd | volume in the duodenal chamber of the GIS |
| Vj | volume in the jejunal chamber of the GIS |
| Vs | volume in the gastric chamber of the GIS |
| Z_D | duodenal dissolution coefficient, considering the pH-dependent dissolution and solubility of loratadine |
| Z_J | jejunal dissolution coefficient, considering the pH-dependent dissolution and solubility of loratadine |
| Z_S | gastric dissolution coefficient, considering the pH-dependent dissolution and solubility of loratadine |